More on Desktop Resources (July 2006)
According to Robert Taketomo, president and CEO of Ventegra, an example of a three-tier injectable benefit design (all tiers subject to a standard deductible and out-of-pocket maximum) would be:
According to Robert Taketomo, president and CEO of Ventegra, an example of a three-tier injectable benefit design (all tiers subject to a standard deductible and out-of-pocket maximum) would be:
The case for injectables
Injectable drugs have been traditionally covered under a medical benefit design with little or no copayment. "With the dramatic increase in the numbers of injectable products being brought to market, health plans are grappling with this issue by shifting coverage for some of these drugs into the pharmacy benefit," Taketomo says. He believes that there are a number of reasons that justify moving injectable drugs into a pharmacy benefit:
Breakthrough T1D Awards $2.8 Million for New Center of Excellence
May 1st 2025The new research center at the University of Michigan and Oregon Health & Science University intends to develop a clinical trial platform that will be used to test several heart and kidney therapies in people living with type 1 diabetes.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
